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ABSTRACT

Obesity is a serious medical condition resulting from excess body fat that triggers
changes in both quantity and quality of various cells that reside in adipose tissue,
including adipose stem cells. Adipose derived stem cells are multipotent, self-renewing
cells that have the ability to differentiate. This process can be controlled by
environmental stimuli, transcription factors, and signal cascades that lead to gene
transcription and protein expression specific to the cell’s fate. The Mediator complex and
the Notch signaling pathway are two complexes that allow this to occur. There is still
much unknown about the Mediator complex, the Notch signaling pathways, and their
interaction, especially during adipogenesis. Here we describe the expression profile and
activity of MED12, Notch1, Notch3, Jagged1, and Jagged2 in self-renewing human
adipose stem cells and determine the impact each gene has on expression and activity in
self-renewing hASC’s. We observed a MED12 knockdown leads to decreased expression
and activation of Notch3; MED12 may be required to regulate the transcript and
expression of Notch3. Notch3 knockdown leads to decrease MED12 transcript and
protein; Notch3 may be required to maintain appropriate levels of MED12 expression.
Jagged1 knockdown leads to a decrease in MED12 transcript, but has no discernable
effects on protein expression. More research is needed to investigate the relationship
between Jagged1 and Notch3.
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CHAPTER 1

INTRODUCTION

1.1 The Potential of Stem Cells
Stem cells are undifferentiated cells that are characterized by their ability to selfrenew and differentiate into a variety of cell types (1). Self-renewal is the process by
which stem cells generate undifferentiated daughter cells, and is required to preserve
stem cell populations in different tissue that can be called upon to aid in development and
tissue repair (2). Stem cells are classified according to their origin and differentiation
potential and may be totipotent, pluripotent, or multipotent (Table 1-1). Totipotent stem
cells have the ability to differentiate into any cell in the body, including extra embryonic
cell types, along with any cells in the three germ layers: endoderm, mesoderm, or
ectoderm (1,3). Pluripotent stem cells also have the ability to differentiate into any cell in
the body, but unlike totipotent stem cells, lack the ability to form extra embryonic tissue
(3). Multipotent stem cells, such as adult stem cells, have the capacity to give rise to
1
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multiple lineages within a defined germ layer, but not all cell lineages in a developing
embryo or adult. These cells are capable of activating or inhibiting a sequence of cellular
and molecular pathways leading to anti-inflammatory and anti-apoptotic effects both in
vivo and in vitro (3). For example, a recent study demonstrated that bone marrow derived
MSCs had the ability to alter the cytokine secretion profile of dendritic cells, effector T
cells, and natural killer cells enabling them to induce a more anti-inflammatory or
tolerant phenotype (4). Because of their activation and inhibitory effects, multipotent
stem cells have gained attention in the scientific community, and been extensively
studied in attempts to find treatments for blood diseases like anemia, auto immune
Type of Stem Cell
by Differentiation
Potential
Totipotent

Sources

Characteristics

Early embryos 1-3
days old

Have the ability to
differentiate into
both embryonic and
extra-embryonic
tissues
Can differentiate
into all of the three
primary germ layers
but cannot
contribute to extraembryonic tissues
Cells that have the
capacity to give rise
to multiple lineages,
but not all cell
lineages in the
developing embryo
or adult

Pluripotent

Cells of
blastocysts 5-14
days old

Multipotent

Bone marrow,
muscle stem cells,
adipocytes in fat,
nerve cells, and
cartilage

Example(s)
Zygote

Embryonic stem
cells, induced
pluripotent stem cells

Mesenchymal stem
cells, Adiposederived stem cells,
Umbilical cord stem
cells

diseases like diabetes, and others due to their potential for cellular therapeutic effects.
Table 1-1: Comparison of stem cell types.

3
1.2 Clinical Potential of Stem Cells
Pluripotent stem cells (PSCs) have the most differentiation potential since they
have the ability to generate somatic cells of all three germ layers. The original pluripotent
stem cells are embryonic stem cells (ESCs) derived from the blastocysts of a 5-14 day old
embryo. PSCs have great therapeutic potential both for their nearly infinite replicative
potential and limitless differentiation potential, and their applications for regenerative
medicine continue to be studied and tested. However, the ethical issues that surround
embryonic-derived pluripotent stem cells and induced pluripotent stem cells have resulted
in significant controversy, limiting their usage and causing researchers to look for
alternatives.
Embryonic stem cells are a type of pluripotent cell derived from the inner cell
mass of pre-implantation embryos. Because human embryonic stem cells are extracted
from human embryos, the ethics and safety behind embryonic stem cell research has been
heavily debated (5). Many people argue that human life begins at conception, therefore
an embryo is equivalent to an adult or live-born child. The extraction process of taking a
blastocyst and removing the inner cell mass to derive an embryonic stem cell line is
considered extremely unethical by some. Aside from this, various privacy concerns are
starting to arise. The use of human biological material for cell-based and clinical research
creates risks to the privacy of both patients and donors. One of these risks is the reidentification of individuals from anonymized cell lines. Risks will continue to increase
as technology and databases used for re-identification become more advanced,
affordable, and accessible. Privacy concerns are increased by policies that require linkage
of cell lines to donors’ clinical information for research and regulatory purposes and
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existing practices that limit research participants’ ability to control what is done with
their genetic data (6).
iPSCs are another type of pluripotent stem cell derived from adult somatic cells
that have been genetically reprogrammed to an embryonic stem cell-like state through the
forced expression of genes and reprogramming factors (7). Although only discovered in
the last two decades, the reprogrammed cells have had much success in clinical trials, and
can be used to generate stem cells for disease modeling, drug development, and
personalized regenerative stem cell therapy (8). Because of this, iPSCs can be used for
modeling monogenic diseases, like Parkinson’s Disease (PD), by using directed
differentiation to derive disease-affected cell types carrying those genotypes. Patientspecific iPSC-derived dopaminergic neurons have been cultured to allow researchers to
study many aspects of the PD phenotypes in a petri-dish, that would otherwise be
inaccessible, helping advance our understanding of degenerative disease (9). In addition
to disease modeling, researchers utilize these cells to improve drug development. iPSCs
allow pharmaceutical companies to test drugs in vitro in a cost-effective manner before
initiating clinical trials. iPSC-derived hepatocytes and cardiomyocyte cardiotoxicity and
hepatotoxicity screens are being used in drug development, with the goal of increasing
the accuracy of safety testing (10). Despite their success, concerns still remain about the
clinical use of iPSCs. Genetic privacy is a challenge since iPSCs contain the genetic
information of the donor. If used carelessly, research and publication could bring about
ethical and legal issues regarding the individual donor and their family’s privacy. In
addition to ethical concerns, uncontrolled proliferation and the potential for unintended
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differentiation of transplanted undifferentiated iPSCs has resulted in the generation of
tumors, making their clinical usage a potential safety issue (11).
More recently, a class of multipotent adult stem cells was discovered that altered
the potential for stem cells in the clinic. Bone marrow-derived mesenchymal stem cells
(MSCs) are the most recognized type of multipotent stem cell. They are found in bone
marrow, adipose tissue, amniotic fluid, and umbilical cord blood and tissue. Because of
their various origins, assigned function in the human body, and multipotent properties,
mesenchymal stem cells have the ability to differentiate into multiple cell types of the
mesodermal lineage such as osteocytes, chondrocytes, myocytes, and adipocytes (12, 13).
Scientists have been studying mechanisms behind MSC proliferation and differentiation
in order to utilize the potential of these cells in regenerative medicine.
In addition to their regenerative ability, all MSCs can secrete soluble factors such
as the immune secretomes prostaglandin E2 (PGE-2), indoleamine 2,3-dioxygenase
(IDO), and nitric oxide (NO) that each contribute towards the inhibition of immune cell
migration, proliferation, differentiation, and activation (14). These cells have been shown
to aid in the treatment of autoimmune diseases including type I diabetes, systemic lupus
erythematosus, and rheumatoid arthritis (15).
Bone marrow derived mesenchymal stem cells (BMCs) have been at the forefront
of current studies due to their successful history of clinical usage, including their use in
treating patients diagnosed with leukemia (16,17). In the case of leukemia, BMCs are
used in the form of bone marrow transplants, a procedure where healthy blood-forming
BMSCs are infused into the body to replace damaged or diseased bone marrow (18).
They have shown to be a promising option for the treatment of cartilage lesions and
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osteoarthritis as well. In a recent study, seventy-two matched patients underwent cartilage
repair using chondrocytes or BMSCs. Clinical outcomes were measured pre-operation as
well as every three months post-operation for two years. They found that BMSCs that
retained their capacity for chondrogenic differentiation could be used to treat cartilage
defects better than chondrocytes. Despite their clinical advantages, bone marrow-derived
mesenchymal stem cells can be a challenging cell source for therapeutic usage due to the
highly invasive and sometimes painful donation procedure, as well as the decline in MSC
number and differentiation potential with increasing age (19). Because of this,
researchers are looking for alternative sources of mesenchymal stem cells.
1.3 Adipose Derived Stem Cells
Human adipose derived stem cells (hASCs) are abundant and easy to access
multipotent stem cells, making them a viable alternative to bone marrow-derived
mesenchymal stem cells (20). With the increasing obesity epidemic worldwide, there has
been an increased desire to understand adipogenesis, and hASCs provide readily
accessible subcutaneous adipose tissue with which to perform critical research (21).
Recently, hASCs have become more predominant in the use of clinical research due to
their potential in regenerative medicine. Research suggests considerable therapeutic
potential for hASCs in tissue engineering, coronary disease, bone regeneration, and
osteoporosis (22). Several studies have used hASCs to study osteoporosis in both
animals and humans (23). A recent study showed how injection of hASCs to
osteoarthritic knees could be used as cell-based therapy, demonstrating that after one year
of regular/one time injection, patients saw significant reduction in pain and improvement
in knee function (24).
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In addition to their potential in regenerative medicine, human adipose stem cells
are also currently being used in cancer treatment centers and in multiple clinical trials due
to their pro-tumorigenic and anti-tumorigenic roles. Current research suggests that the
role of hASCs depends on their origin, the cell line of the cancer being studied, and the
cells of the host immune system (25, 26). Human ASCs do possess tumorigenic
properties because they secrete cytokines, growth factors like vascular endothelial growth
factors (VEGF), and chemokines like platelet-derived growth factors (PDGF), that
modulate angiogenesis and immune responses, as well as facilitate the regeneration of
damaged tissues (27). VEGF is a homodimeric glycoprotein that is considered to be the
key mediator of angiogenesis. In healthy humans, VEGF promotes angiogenesis in
embryonic development, and is important in wound healing. It also plays a role in cancer,
because angiogenesis is essential for cancer tumor development and growth (28).
Similarly, PDGFs are pro-angiogenic factors found in platelets. The PDGF signaling
pathway has been extensively studied, and found to regulate several cellular processes
such as proliferation, migration, and metastasis (27). Recent studies have shown the
PDGF signaling pathway and Notch signaling pathway are linked, and that their
synchronization controls vascular differentiation (29).
1.4 Adipogenesis
Adipogenesis is the process of adipocytes developing and accumulating to form
adipose tissue at various sites in the body. During this process, the preadipocytes no
longer proliferate, and instead begin to accumulate lipid droplets as well as develop
characteristics of mature adipocytes like morphological changes, cessation of cell growth,
expression of lipogenic enzymes, and the establishment of sensitivity to hormones like
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insulin (30). The main role of adipocytes is to store excess energy in the form of fat and,
during energy scarcity, be used to meet the energy demand of other organs. Adipocytes
arise during late embryonic development, as well as in the developed organism under
conditions that promote obesity such as physical inactivity, overeating, or disease (31).
For adipogenesis to occur, preadipocytes must undergo adipocyte determination
and differentiation, which is controlled by a complex regulatory network including a
variety of environmental stimuli, transcription factors, and signal cascades that lead to
gene transcription and protein expression specific to the cell’s fate (Figure 1-1). Both
determination and differentiation are tightly regulated, with cross-talk between them that
ultimately determines cell type, function, and behavior (32). Many of the molecular
details regarding adipogenesis are still unknown, but several factors involved in
adipogenesis have been identified.
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Figure 1-1: Gene Expression. Gene expression is controlled by a complex
regulatory network. Environmental stimuli initially activate signal transduction
pathways. Once signaling components are activated, they can directly affect
transcription factors and chromatin modifiers to initiate or inhibit transcription.
When a gene is transcribed, transcription factors are activated and translocated into
the nucleus of a cell to initiate transcription. If a gene target is repressed, chromatin
is modified and condensed to prevent transcription.

The current hypothesis suggests that terminal adipocyte differentiation requires
transcription factors peroxisome proliferator-activated receptor gamma (PPARγ),
CCAATT enhancer binding proteins (C/EBPs), and the basic helix-loop-helix protein
ADD-1/ SREBP-1. PPARγ, controls terminal differentiation of adipocytes, and is
required for maintaining their differentiated state (33). Adipogenesis is believed to be
controlled by a transcriptional cascade, initiated when chromatin is open by the binding
of C/EBPβ. During the initial phases of adipogenesis, C/EBP is expressed in response to
adipogenic hormones such as insulin or glucocorticoids, which in turn signals the
transcription of PPARγ (32). ADD-1/SREBP-1c is also expressed during terminal
adipocyte differentiation, and accelerates adipocyte differentiation, regulates the
expression of PPARγ, and provides ligands for this receptor. Finally, terminal adipocyte
differentiation requires the concerted action of PPARγ and C/EBP. Those cells re-enter
the cell cycle after hormonal induction, arrest proliferation again and undergo terminal
adipocyte differentiation (34). Overall, the factors that regulate adipogenesis either
promote or block the cascade of transcription factors that coordinate the differentiation
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process. Other transcription factors such as insulin-like growth factors (IGF-1) have been
shown to be critical for the survival, proliferation, and differentiation of pre-adipocytes
(35). In addition to the cellular environmental factors, age, sex, and lifestyle have also
been shown to impact adipogenesis (21) (Figure 1-2).

1

2

3

Figure 1-2: Human adipose derived stem cell differentiation. Mesenchymal stem
cells (1) proliferate and develop into preadipocytes (2) after reaching confluency.
Preadipocytes become adipocytes through adipogenesis (3). At the molecular level,
the core process of adipogenesis is regulated by transcription factors, such as
CCAAT/enhancer, binding protein α (C/EBP-α), and peroxisome proliferator
activated receptor γ (PPARγ), a heterodimerization partner of Retinoic X receptors
(RXRs). The concerted action of these adipogenic transcription factors ultimately
drives the expression of adipocyte specific factors such as enzymes responsible for
the synthesis and storage of triglycerides in lipid droplets (34).
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1.5 Mediator Complex
Transcription factors bind to DNA directly, but in order for transcription to occur,
these factors must be able to communicate across long stretches of the genome from
enhancer elements to the promoter where RNA polymerase II is bound (8). The Mediator
complex is a multiprotein complex that allows this cell-type specific gene expression
communication to occur (36). As mentioned previously, stem cells are able to self-renew
or differentiate into multiple cell types depending on how gene expression is regulated
(1). Self-renewal and differentiation cannot take place at the same time; therefore, the
cell’s fate can be regulated by altering the function and expression of the general
transcription factors (GTFs). GTFs assemble the transcription preinitiation complex (PIC)
on gene promoters, as well as assemble activators and repressors that bind to gene
regulatory elements located either upstream or downstream of promoters, and the
essential coactivator of cell type-specific genes like the Mediator complex. The fate of
any stem cell is ultimately determined by regulating the transcription of specific genes, a
feature largely facilitated by the Mediator complex (37).
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Figure 1-3: Mediator Complex Facilitates Transcription. Top: linear
representation of a super-enhancer. Grey ovals represent DNA-bound transcription
factors and orange circles represent the histone mark H3K27Ac, a mark of gene
activation, with the gene promoter potentially located over 10 kilobases downstream
of the super-enhancer. Bottom: DNA looping mediated by the Mediator complex and
Cohesion, which bridge the transcription factor-bound enhancer or super enhancer
element to the gene promoter, facilitating expression of the cell-type specific gene
(37).

In order for transcription to occur, transcription factors must be able to
communicate across long stretches of the genome from enhancer elements to the
promoter where RNA polymerase II is bound (38). The Mediator complex plays a vital
role in the regulation of cell-type specific transcription in eukaryotic cells by linking
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transcription factors to RNA polymerase II. It is considered to be a global regulator of
gene expression, and has an extremely dynamic design (36). Overall, Mediator consists
of four modules: a head, a middle, a tail, and a kinase module (Figure 1-4). The head and
middle modules contain the most highly conserved subunits, and maintain cell viability
and overall gene expression. The tail recruits specific transcription factors to direct and
maintain lineage commitment. In the Mediator complex, the kinase module CDK8
attaches to Mediator core complex and either activates or suppresses transcription
through RNA polymerase II. The kinase module also functions independently of the
Mediator complex. RNAPII, TFIIH, histone H3, and MED13 have all been listed as
substrates for the CDK8 kinase (39).
CDK8 is considered both an oncogene and a tumor suppressor, and it promotes
cell growth via the serum response pathway. CDK8 is a part of the 30 subunit Mediator
(MED) complex, which acts as a molecular bridge to mediate transduction of regulatory
signals. It completes this task by using a module that consists of Cyclin C (CCNC),
MED12, and MED13 (38). A recent study suggests a relationship between MED12 and
Notch signaling in chronic lymphocytic leukemia cells. They found CDK8 is recruited to
the MED12 subunit in order to either activate or repress transcription. Once in place,
CDK8 interacted with the kinase module, Cyclin C, MED12, and MED13, causing the
complex to control transcription by RNA Polymerase II. They found if MED12 was
mutated or absent, it did not interact with the CDK8 kinase and the Notch Intracellular
Domain (NICD) was not phosphorylated, leading to an increase in Notch activity and
transcription activation. Overall, the absence of control leads to the activation of Notch,
causing uncontrolled cell differentiation or cell proliferation (40). This recent report
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indicates the need for further investigation in order to better understand the interaction
and relationship of these proteins in controlling hASC self-renewal and move stem cell
research and clinical application forward.

D

A
B
C
Figure 1-4: The Mediator Complex. The head (A) and middle (B) modules contain
the most highly conserved subunits, and maintain cell viability and overall gene
expression. The tail (C) recruits specific transcription factors to direct and maintain
lineage commitment. The kinase module (D) CDK8 attaches to Mediator core complex
and either activates or suppresses transcription through RNA polymerase II.

1.6 Notch Signaling
The Notch signaling pathway is an evolutionarily conserved cell fate
determination pathway present in all multicellular eukaryotic organisms that controls cell
differentiation, proliferation, and apoptosis (41). The pathway consists of four Notch
receptors (Notch 1-4) and five canonical ligands (Jag-1, Jag-2, DLL-1, DLL-3, and DLL4), as well as intracellular proteins that transmit signals to cells (42). The Notch signaling
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pathway directly couples events at the cell membrane with the regulation of transcription.
Most of the ligands in the Notch signaling pathway are also transmembrane proteins,
therefore much of the signaling is restricted to neighboring cells. Through the canonical
pathway, receptors on a given cell are activated in a contact dependent manner by cell
surface ligands (Jagged1-2, DLL1, DLL3, DLL4) from neighboring cells in a process
known as trans-activation. Each Notch receptor has three functional domains: The Notch
extracellular domain (NECD) which is present on the outside of the cell, the Notch
intracellular domain (NICD) which is present on the inside of the cell, and the Notch
transmembrane domain (TM) which connects the NECD and NICD (43). The “sending
cell” contains more ligands than Notch receptors, and the “receiving cell” contains more
Notch receptors than ligands (44). When the cell-surface Notch receptor interacts with a
ligand, the NECD binds to it. In order for the Notch signaling pathway to become
activated, the ligands need to become activated (43). This happens by a protein known as
“mind bomb” (Mib) in the sending cell, which ubiquitinates the ligand. Once activated,
the ligand binds to the NECD, and a protease known as ADAM cleaves the NECD from
the receiving cell; this is known as S2 cleavage. Gamma secretase then cleaves the NICD
off the TM portion of the Notch receptor in a process known as S3 cleavage. This causes
NICD to be free in cytosol, allowing it to bind to a complex of proteins including CSL
which further binds to P300 (42). This entire complex translocates into the nucleus of the
cell. This can lead to the transcription of Notch target genes such as CyclinD3, which is a
critical regulator of the cell cycle in pro and large pre-B cells. Once the Notch target
genes have been expressed, NICD is down regulated. In order for trans-activation to
occur, the intracellular domain must be cleaved, and travel to the nucleus to regulate
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transcription. This is what ultimately influences cell division, fate, and death in
metazoans (43).
Because the Notch signaling pathway controls cell differentiation, proliferation,
and apoptosis, it is often associated with tissue growth, cell death, tumor suppression, and
cancer. In humans, the misregulation or loss of Notch signaling has been proven to be the
underlying cause of multiple diseases and cancer (43). Recent evidence shows that
germline mutations in jag1 and notch2 cause Adams-Oliver syndrome, and mutations in
dll3 cause spondylocostal dysostosis. Mutations in the notch1 receptor are associated
with several types of cardiac disease, and mutations in notch3 cause the disorder cerebral
autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL) (45). DLL4-Notch3 signaling in human vascular organoids induces
basement membrane thickening and drives vasculopathy in the diabetic
microenvironment (46). By contrast, somatic alterations in the genes encoding Notch
signaling components drive various types of human cancer, such as breast cancer, smallcell lung cancer (SCLC) and T-cell acute lymphoblastic leukemia (T-ALL) (47).
Notch1 signaling is a highly conserved pathway that has been proven to play a
pertinent role in stem cell hemostasis and tissue development. In adipocyte progenitor
cells, Notch1 signaling regulates the adipogenesis process including proliferation and
differentiation of the adipocyte progenitor cells in vitro (48).
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Figure 1-5: The Notch Signaling Pathway. The Notch Signaling Pathway is an
evolutionarily conserved pathway in multicellular organisms that regulates cell-fate
determination during development and maintains adult tissue homeostasis. Notch
receptors are single-pass transmembrane proteins composed of functional
extracellular (NECD), transmembrane (TM), and intracellular (NICD) domains. In
mammalian signal-sending cells, members of the Delta-like (DLL1, DLL3, DLL4) and
the Jagged (JAG1, JAG2) families serve as ligands for Notch signaling receptors.

1.7 Motivation
As mentioned previously, stem cells are undifferentiated cells that are
characterized by their ability to self-renew and differentiate into a variety of cell types.
The process of self-renewal, which generates undifferentiated daughter cells, is required
to preserve stem cell populations in different tissue (2). Adult mesenchymal stem cells
are found in bone marrow, blood vessels, skeletal muscle, epithelium, adipose tissue, and
more (12,13). Human adipose-derived stem cells (hASCs) are a type of multipotent stem
cell that are abundant in adipose tissue and easy to access, making them an increasingly
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more viable alternative to bone marrow-derived mesenchymal stem cells which are being
used in research today (20).
Scientists have been studying the mechanisms behind MSC proliferation and
differentiation in order to utilize the potential of these cells in regenerative medicine.
They have shown in recent clinical studies to have considerable therapeutic potential in a
multitude of areas, including tissue engineering, coronary disease, bone regeneration, and
osteoporosis (17,19). If we can extend studies to degenerative diseases like Muscular
dystrophies (MD) and Parkinson’s disease, we may be able to not only stop these
disease’s effects, but also reverse the damage these diseases have caused. In order to
progress these studies, we must understand the underlying mechanisms that allow stem
cells to remain self-renewing and multipotent.
Both the Mediator complex and the Notch signaling pathway work in unison to
control the fate of ASCs through the regulation of gene expression. The Mediator
complex plays a vital role in the regulation of cell-type specific transcription in
eukaryotic cells by linking transcription factors to RNA polymerase II. The Notch
signaling pathway is an evolutionarily conserved cell fate determination pathway that
controls cell differentiation, proliferation, and apoptosis (41). Although we know
interaction between Mediator and Notch is critical to controlling the generation of healthy
tissue, the relationship between Mediator and Notch remains poorly defined. Research
has been trying to bridge the two in attempt to better understand the underlying
mechanisms that allow stem cells to remain self-renewing and multipotent, but more
research is needed.

CHAPTER 2

METHODS

2.1 Thawing Human Adipose Stem Cells
Human adipose stem cells (Obatala, #70926) were removed from liquid nitrogen
and thawed in a 37˚C water bath. Once thawed, cells were transferred into a 15 mL
conical vial containing 4mL of pre-warmed Complete Culture Media (CCM) composed
of 203.75mL of Minimum Essential Medium Alpha (Life Technologies, #12561049),
41.25mL of Fetal Bovine Serum (Atlanta Biologicals, #S11550), 2.5mL of L-Glutamine
(Gibco, # 25030-081), and 2.5mL of Penicillin-Streptomycin (Life Technologies,
#15140122). Cells were centrifuged at 1500 RPM for 10 minutes. The supernatant was
removed from the newly formed cell pellet via aspiration, and the cell pellet was
resuspended in 1mL of CCM. Media was changed 24 hours after the initial thaw, as well
as every 48 hours after until cell confluency reached 70-80% and they were ready to be
passaged.

19

20
2.2 Passaging
When the cells reached 70-80% confluency, they were rinsed with 5 mL of prewarmed phosphate buffered saline (PBS) (Life Technologies, #10010023). The PBS was
aspirated off the plate and then 3mL of 0.25% Trypsin (Life Technologies, #25200-056)
was added to the plate. The cells were incubated for 3 minutes at 37˚C, then checked
under a microscope for lifting. 6mL of CCM (or double the amount of trypsin) was then
added to the plate and the cells were collected into a conical tube with a pipette for
centrifugation at 1500 RPM for 10 minutes. Supernatant was aspirated off and the cells
were resuspended in 1mL of pre-warmed CCM. 20µL of the cell solution and 20µL of
trypan blue were mixed in an Eppendorf tube. Once mixed, 10µL of the cell-trypan
solution was added onto both sides of a FL hemocytometer, and the slide was inserted
into a cell counter. After cells were counted, they were then passaged onto 6cm plates
and placed in an incubator for 24 hours (Table 2-1).
Table 2-1: Plating table
Plate size

Number of cells seeded

10cm plate

100,000 cells

6cm plate

45,000 cells

6-well plate

20,000 cells per well
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2.3 Transfection
When the cells reached 50-60% confluency, they were transfected with either a
silencer select control No. 1 siRNA (Thermo Scientific, #4390843) or a custom target
gene siRNA for Notch1 (Thermo Scientific, #am16708), Notch3 (Thermo Scientific,
#4392420), Med12 (Thermo Scientific, #s19364), Jagged1 (Thermo Scientific,
#AM16708), or Jagged2 (Thermo Scientific, #4392420). Cells were transfected using
RNAi Max Lipofectamine following manufacturer’s protocol. Cells were incubated at
37˚C overnight and the next day media was replaced with pre-warmed CCM. Media was
re-plated with CCM the next day and either RNA or protein was collected 72 hours after
the transfection.
2.4 RNA
2.4.1

RNA Collection
72 hours after the transfection, plates were rinsed with pre warmed PBS and RNA
was collected using 500µL of Trizol per 6cm plate. Plates were scraped using a cell
scraper for 1 minute and the solution was collected into 1.5 mL Eppendorf tubes and
stored in a -80˚C freezer.

2.4.2

RNA Extraction
Trizol samples was thawed at room temperature and 100µL of chloroform
was added to each RNA sample. Each sample was then vortexed for 15 seconds and left
to incubate at room temperature for 3 minutes. Once the incubation was complete, the
samples were centrifuged at 4˚C at 12000G and the colorless aqueous supernatant was
removed and placed into a new Eppendorf tube. 5µL of Thermo Scientific glycogen
along with 250µL of 100% isopropyl was added to each sample and each tube was
inverted 3 times before it was left to incubate at room temperature for 10 minutes.
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Samples were then centrifuged at 4˚C at 12000G for 10 minutes. The liquid
supernatant was removed leaving only the RNA pellet. 1mL of 75% ethanol was added to
the pellet and then vortexed to wash the pellet. The samples were then centrifuged for 5
minutes at 4˚C at 7500G. After the samples were centrifuged, the liquid supernatant was
removed and the pellet was allowed to air dry, before 30µL of nuclease free water was
added to RNA pellet. RNA was quantified to assess concentration and purity using the
BioTek plate reader. The Gen5 Microplate Reader and Imager Software was used to
analyze the data.
2.4.3

cDNA Synthesis
cDNA was synthesized for each sample using 1microliter of RNA and qScript
cDNA supermix (VWR, # 95048-100) following the manufacturer’s protocol.

2.4.4

Endpoint RT PCR
Primers and quality of cDNA were confirmed by endpoint RT-PCR using GoTaq
green mastermix (Promega, #M7122) following manufacturer’s protocols.
Table 2-2: Primer list
Gene

med12

notch1-2

Forward Sequence

Reverse Sequence

CGAAAAGGGACAGC

CCCATCCTCCCC

AGAAAC

ACCTAAGA

CACGCTGACGGAGTA

GGCACGATTTCC

CAAGT

CTGACCA

Product

Temperatu Cycles

size (bp)

re

87

60

30

56

60

35
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notch3

jagged1

jagged2

gapdh-2

CACCCTTACCTGACC

TTCGGACCAGTC

CCATCC

TGAGAGGGA

GGCACGCGTCATTGT

TGCGCAGCCTTT

GTTAC

TATTCCCT

TGGACGCCAATGAGT

CCCGGGATGCAA

GTGAA

TCACAGTA

ACTAGGCGCTCACTG

CAATACGACCAA

TTCTCT

ATCCGTTGACT

81

60

35

119

60

35

91

60

35

99

60

30

2.5 Real Time
Quantitative reverse transcriptase PCR (qRT-PCR) was performed using Power
SYBR® Green PCR Master Mix and run using an Applied Biosystems StepOne Plus
machine. GAPDH (Abcam, # ab9485) was used for normalization of qRT-PCR results.
Samples were run in triplicate.

2.6.1

2.6 Protein
Extraction and Collection
When cells reached 70-80% confluency, plates were rinsed with cold PBS. Cells
were collected in lysis solution composed of Pierce RIPA Buffer (Thermo Fisher
Scientific, #89900) and Halt Protease and Phosphate inhibitor (Thermo Fisher Scientific,
#78441) and transferred into 1mL Eppendorf tubes where they maintained constant
agitation for 30 minutes at 4˚C. They were then centrifuged at 12000 RPM for 20 minutes
at 4˚C and the supernatant was transferred into a new Eppendorf tube.
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2.6.2

Bradford Assay
Protein concentrations were measured using Bio-Rad Protein Assay Dye Reagent
Concentrate (Bio-Rad, #5000006) following manufacturer's protocol. Absorbance was
measured at a wavelength of 595 nm.

2.6.3

Western Blots
Equivalent amounts of protein were used for all samples, samples were boiled
with water and 2x laemmli sample buffer (Bio-Rad, #1610737) in a heat block at 95-100
degrees F for 10 minutes before being loaded into the gel. Protein samples ranged from
20-40 microliters with the laemmli buffer amount and water dependent on the protein
number calculated from a Bradford Assay. Once boiled, 35 microliters of each sample
were loaded along with 7 microliters of ladder on the end into a 4-15% polyacrylamide
gel. The gel was run at 120 volts for one and a half hours. Proteins were transferred on a
Trans-Blot Turbo Mini PVDF Transfer using the Bio-Rad Trans-Blot Turbo Transfer
System. The membranes were then blocked using a 5% blocking buffer composed of
nonfat dry milk and TBST, and probed overnight with a primary antibody (Table 2-2).
The membranes were washed with TBST and probed with a secondary antibody for 60
minutes. After being washed, the membranes were then imaged with Bio-Rad clarity
western ECL substrate and analyzed using ImageJ software.

Table 2-3: Antibody List
Antibody

Dilution

Company

Catalog #

MED12

1:1000

Bethyl

A3000-774A

Notch1

1:1000

Proteintech

20687-I-AP
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JAG1

1:1000

Cell signaling

2620S

JAG2

1:1000

Cell signaling

2205S

GAPDH

1:3000

abcam

Ab9485

Goat pAb to Rb IgG

1:10000

abcam

Ab6721

(HRP)

26

CHAPTER 3

THE EFFECT OF NOTCH SIGNALING ON MEDIATOR SUBUNITS

3.1 Introduction
Human adipose stem cells (hASCs) are a type of multipotent stem cell that have
recently risen to the forefront of research due to their ability to serve as an alternative to
pluripotent embryonic stem cells, induced pluripotent stem cells, or even the more
invasively derived bone marrow stem cells (BMSCs). Scientists have been using hASCs
to study the mechanisms behind adult stem cell proliferation and differentiation in order
to utilize the potential of these cells in regenerative medicine, cell-based therapies, and
tissue engineering. If we can gain a better understanding of how to control hASC
differentiation and self-renewal, stem cells could be used to their full potential in
regenerative medicine.
The Notch signaling pathway is a highly conserved pathway that has several roles
in cellular maintenance including proliferation, differentiation, and apoptosis. It has also
been found to participate in the conversion of mesenchymal stem cells (MSCs) to mature
adipocytes, but its overall role in adipogenesis remains controversial with conflicting
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research indicating a context-dependent positive and negative role for Notch signaling.
Notch signaling is known to directly couple events at the cell membrane with the
regulation of transcription.
Through the canonical pathway, receptors on a given cell are activated in a
contact dependent manner by cell surface ligands (Jagged1-2, DLL1, DLL3, DLL4) from
neighboring cells in a process known as trans-activation. The canonical ligands are type 1
cell-surface proteins that ultimately control the sending and receiving of signals, and have
multiple epidermal growth factor (EGF) repeats in their extracellular domains. Notch
receptors undergo conformational changes once trans-activation occurs, allowing for two
consecutive proteolytic cleavage events that release the intracellular region of the Notch
receptor into the cell’s cytoplasm. The EGF in the ligands serves as a protection against
proteases, which prevents Notch1 from ligand-independent activation (49). Once in the
cytoplasm, the receptor can then travel to the nucleus to induce gene transcription.
Because both the Notch receptor and its ligands play crucial roles in gene transcription,
dysregulated Notch signaling is associated with developmental abnormalities and cancer.
In humans, haploinsufficiency of either Jagged1 or Notch2 is associated with Alagille
syndrome, while Notch1 haploinsufficiency is implicated in a subtype of inherited aortic
disease (50).
At the center of cell-type specific transcriptional regulation is Mediator, a highly
conserved complex that links pathways like Notch to gene promoters. Both Mediator and
the Notch signaling pathway work in unison to control the fate of hASCs through the
regulation of gene expression, but their relationship remains poorly defined. A recent
study found that in order to activate or repress transcription, CDK8 is recruited to the
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MED12 subunit, which suggests a possible influence of MED12 on Notch signaling in
chronic lymphocytic leukemia cells (51). Once in place, CDK8 interacts with the rest of
the kinase module, Cyclin C, MED12, and MED13, causing the complex to activate or
suppress transcription by RNA Polymerase II. In this study, MED12 effects Notch
signaling by functioning as an activator of Cyclin C/CDK8. If MED12 is mutated or
absent, it does not interact with the CDK8 kinase and the Notch Intracellular Domain
(NICD) is not phosphorylated, leading to an increase in Notch activity and transcription
activation. This recent report indicates the need for further investigation in order to better
understand the interaction and relationship of these proteins in controlling hASC selfrenewal.
Although there are four modules of the Mediator complex, the kinase module
consisting of CDK8, Cyclin C, MED12, and MED13 remains of particular interest given
its unique role both as part of the core complex and in its ability to act independently.
MED12 in particular is under investigation as it is believed to regulate and control
transcription in hASCs. Studies have shown that MED12 has a role in pluripotent stem
cell self-renewal, could be involved in several human developmental defects, and may be
responsible for many diseases, including Lujan syndrome (52).
Previous data from the Newman lab investigated the relationship between MED12
and Notch1. The results indicated that Notch1 does not have an active role hASC selfrenewal. Med12 transcript was not significantly affected by the knockdown of notch1,
and protein expression of MED12 was not affected by a Notch1 knockdown (Figure 3-1
and Figure 3-2). In addition, transcript levels of notch1 decreased after the knockdown of
med12, but protein levels of Notch1 were not affected by the MED12 knockdown (Figure
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3-3 and Figure 3-4), suggesting a minimal role if any for this receptor in hASCs cultured
under standard conditions (Figure 3-3 and Figure 3-4) (53).

B

A

P value= 0.00018

P value= 0.240368323

Figure 3-1: Notch1 knockdown has no effect on med12 transcript. A. The notch1
knockdown was validated by qRT-PCR. B. med12 transcript was measured following
the siRNA-mediated knockdown of notch1. No significant reduction in the med12
transcript level was observed. Data was normalized to gapdh. P values were
calculated with T Test, N=3. Image courtesy of Jaylen Mumphrey.

Figure 3-2: Notch1 knockdown has no effect on MED12 protein levels. Protein
expression levels of hASCs transfected with notch1 siRNA were assessed via Western
blot. GAPDH was used as a loading control and unfortunately showed decreased
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expression in the Notch1 knockdown samples. As it is a loading control for
normalization, it’s levels should not have change. Therefore, the protein levels also
do not clearly indicate sufficient KD of Notch1. This suggests possible inconsistency
in loading and requires reexamination. MED12 did not appear to be affected by the
Notch1 knockdown, and active Notch1 (N1 Cleaved) was undectable despite a slight
signal in full length (FL) Notch1. Image courtesy of Jaylen Mumphrey. NC Negative
control, KD knockdown, N1 Notch1, FL Full Length, MED12 Mediator12.
A

B

P value= .0000325

P value= 0.025110258

Figure 3-3: MED12 knockdown leads to decreased Notch1 transcript. MED12
siRNA effectively knockdowns med12 transcript and diminishes expression of Notch1.
Transcript levels of med12 (A) and notch1 (B) in hASCs transfected with med12
siRNA analyzed via qRT-PCR. There was not a significant reduction in the notch1
transcript levels. Data was normalized to gapdh. P values were calculated with T
Test, N=3. Image courtesy of Jaylen Mumphrey.
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A

B

P value= 0.0285528

Figure 3-4: MED12 knockdown has no effect on Notch1 protein levels. A. Protein
expression levels of hASCs transfected with MED12 siRNA via Western blot. The
MED12 knockdown was validated while the identification of Notch1 was
unsuccessful. B. ImageJ data showing the MED12 knockdown Western blot
quantified using ImageJ software. Western blot was normalized to GAPDH. P values
were calculated with T Test. N=3. Image courtesy of Jaylen Mumphrey. NC Negative
control, KD knockdown, N1 Notch1, FL Full Length, MED12 Mediator12.
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To validate and expand on these results, I investigated the relationship between
Notch1, Notch3, the Mediator kinase subunit MED12, and Notch ligands during hASC
self-renewal.

3.2 Results
Notch1 KD leads to a decrease in med12 transcript in self-renewing hASCs
In order to further investigate the relationship between Notch and Mediator and
confirm previous studies in the Newman lab, we analyzed the influence of Notch1 on
MED12. Human adipose stem cells were transfected with notch1-specific siRNA.
The knockdown of notch1 was validated using qRT-PCR. Notch1 transcript was
reduced in comparison to negative controls, with less than 80% transcript remaining
after knockdown (Figure 3-5). The expression of med12 was evaluated using qRTPCR and showed a slight decrease in transcript compared to negative controls, with
less than 40% remaining after knockdown, but the data was not significant (Figure 36).

1.4
1.2
1
0.8
0.6
0.4
0.2
0
Negative siRNA

Notch1 siRNA

P = 0.000754

Fold change

Notch1
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Figure 3-5: Notch1 knockdown leads to a decrease in notch1 transcript. Transcript
expression levels of notch1 in hASCs transfected with notch1 siRNA for 72 hours
analyzed via qRT-PCR. Data was normalized to GAPDH. N=3.

MED12
1.4

Fold change

1.2
1
0.8
0.6
0.4
0.2
0
Negative siRNA

Notch1 siRNA

P = 0.642208

Figure 3-6: Notch1 knockdown leads to a decrease in med12 transcript. Transcript
expression levels of med12 hASCs transfected with notch1 siRNA for 72 hours
analyzed via qRT-PCR. Data was normalized to GAPDH. N=3.

Notch1 KD leads to an increase in notch3 transcript in self-renewing hASCs
In order to further investigate the relationship between the Notch receptors, we
analyzed the influence of Notch1 on Notch3. Human adipose stem cells were
transfected with notch1-specific siRNA. The knockdown of notch1 was validated
using qRT-PCR. Notch1 transcript was reduced in comparison to negative controls,
with less than 80% transcript remaining after knockdown (Figure 3-5). The
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expression of notch3 was evaluated using qRT-PCR and showed an increase in
transcript compared to negative controls, but the data was not significant (Figure 3-7).

Notch3

Fold change

10
8
6
4
2
0
Negative siRNA

Notch1 siRNA

P = 0.541943

Figure 3-7: Notch1 knockdown leads to an increase in notch3 transcript.
Transcript expression levels of notch3 hASCs transfected with notch1 siRNA for 72
hours analyzed via qRT-PCR. Data was normalized to GAPDH. N=3.

Notch1 KD leads to a decrease in jagged1 transcript in self-renewing hASCs
In order to further investigate the relationship between Notch and Mediator, we
analyzed the influence of Notch1 on Jagged1. Human adipose stem cells were
transfected with notch1-specific siRNA. The knockdown of notch1 was validated
using qRT-PCR. Notch1 transcript was reduced in comparison to negative controls,
with less than 40% transcript remaining after knockdown (Figure 3-8). The
expression of jagged1 was evaluated using qRT-PCR and showed a slight decrease in
transcript compared to negative controls, with less than 80% remaining after
knockdown (Figure 3-9).
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P = 0.01652

Figure 3-8: Notch1 knockdown leads to a decrease in notch1 transcript.
Transcript expression levels of notch1 hASCs transfected with notch1 siRNA for 72
hours analyzed via qRT-PCR. Data was normalized to GAPDH. N=3.
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Figure 3-9: Notch1 knockdown leads to a decrease in jagged1 transcript.
Transcript expression levels of jagged1 hASCs transfected with notch1 siRNA for 72
hours analyzed via qRT-PCR. Data was normalized to GAPDH. N=3.

Notch1 KD leads to an increase in jagged2 transcript in self-renewing hASCs
Since the knockdown of notch1 appeared to result in a decrease in transcription of
jagged1, the relationship between Notch1 and Jagged2 needed to be investigated.
hASCs were transfected with notch1 siRNA to determine if it had any effect on
jagged2 transcript. Human adipose stem cells were transfected with notch1- specific
siRNA. The knockdown of notch1 was validated using qRT-PCR. Notch1 transcript
was reduced in comparison to negative controls, with less than 40% transcript
remaining after knockdown (Figure 3-8). The expression of jagged2 was evaluated
using qRT-PCR and showed a slight decrease in transcript compared to negative
controls, with less than 80% remaining after knockdown, but the data was not
significant (Figure 3-10).
Jagged2
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Figure 3-10: Notch1 knockdown leads to an increase in jagged2 transcript.
Transcript expression levels of jagged2 hASCs transfected with notch1 siRNA for 72
hours analyzed via qRT-PCR. Data was normalized to GAPDH. N=3.

MED12 KD leads to decreased expression and activation of Notch3 in self-renewing
hASCs
In order to further investigate the relationship between Notch and Mediator, we
analyzed the influence of MED12’s effect on Notch3. Human adipose stem cells were
transfected with med12-specific siRNA. The knockdown of med12 was validated
using qRT-PCR and Western Blot. Med12 transcript was reduced in comparison to
negative controls, with less than 40% transcript remaining after knockdown (Figure
3-11A). The expression of notch3 was evaluated using qRT-PCR and showed a slight
decrease in transcript compared to negative controls, with less than 80% remaining
after knockdown (Figure 3-11B). The knockdown of MED12 was further validated
through Western Blot (Figure 3-12A and B). Notch3 was affected by the knockdown
of MED12, where the knockdown caused an increase in full length (FL) Notch3 and a
decrease in cleaved Notch3 (53) (Figure 3-12C and D).
A

B

P value= 0.0000325

P value= 0.003754448
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Figure 3-11: Med12 knockdown leads to reduction in notch3 transcript. A. The
med12 knockdown was validated by qRT-PCR. B. Analysis of notch3 transcript
following the knockdown of MED12. Data was normalized to gapdh. N = 3. Image
courtesy of Jaylen Mumphrey.

A

C

B

D

Figure 3-12: MED12 knockdown leads to reduction in Notch3 protein levels. A.
Effect of MED12 knockdown on full length (FL) Notch3, cleaved Notch3, and
MED12. GAPDH was used as a loading control. B. ImageJ analysis of a Notch3
knockdown effects on Med12. P values were calculated with T Test, N=3. C. Effect of
MED12 knockdown on full length (FL) Notch3. P values were calculated with T Test,
N=3. D. Effect of MED12 knockdown on cleaved Notch3. P values were calculated
with T Test, N=3. Images courtesy of Jaylen Mumphrey. NC Negative control, KD
knockdown, N3 Notch3, FL Full Length, MED12 Mediator12.
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MED12 KD does not affect Jagged ligand expression in self renewing hASCs
In order to further study the relationship between Mediator and Notch, we
monitored changes in the Notch signaling canonical pathway ligands Jagged1 and
Jagged2. Human ASCs were again transfected with med12-specific siRNA, and jagged1
and jagged2 transcript were evaluated using qRT-PCR. Med12 knockdown was validated
using qRT-PCR and was significantly reduced in comparison to negative controls, with
only 10% transcript remaining after knockdown (Figure 3-13). A slight increase in
jagged1 and jagged2 transcript was observed following the knockdown of med12, but
neither were significantly affected. These data suggests that neither jagged1 nor jagged2
transcript is affected by MED12 (Figure 3-14). Unfortunately, the effects of a MED12
knockdown on JAG and JAG2 protein expression was unable to be confirmed through
Western Blot. MED12 was shown to have a decrease in expression confirming the
knockdown, but JAG1 and JAG2 did not show up and were unable to be analyzed (Figure
3-15 and Figure 3-16).

MED12

P value= 0.000114
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Figure 3-13: Med12 knockdown leads to a decrease in med12 transcript.
Transcript expression levels of med12 hASCs transfected with med12 siRNA for 72
hours analyzed via qRT-PCR. Data was normalized to GAPDH. N=3.

B

A

P value= 0.106797

P value= 0.371344063

Figure 3-14: Med12 knockdown does not significantly affect jagged1 and jagged2
transcript. Transcript expression levels of hASCs transfected with med12 siRNA for
72 hours analyzed via qRT-PCR. Jagged1 (A) and jagged2 (B) expression levels
slightly increased but neither were significant. Data was normalized to GAPDH.
N=3.
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NC1 NC2 NC3 KD1 KD2 KD3

MED12

JAG1

GAPDH

Figure 3-15: Identification of MED12 KD effect on JAG1 protein levels was
unsuccessful. Protein expression levels of hASCs transfected with MED12 siRNA via
Western blot. Knockdown of MED12 was successful but identification of Jagged1
(JAG1) protein was unsuccessful. NC Negative control, KD knockdown, MED12
Mediator12, JAG1 Jagged1. N=3.
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MED12

JAG2
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Figure 3-16: Identification of MED12 KD effect on JAG2 protein levels was
unsuccessful. Protein expression levels of hASCs transfected with MED12 siRNA via
Western blot. MED12 knockdown was successful, but identification of Jagged2
(JAG2) protein was unsuccessful. NC Negative control, KD knockdown, MED12
Mediator12, JAG2 Jagged2. N=3.

Jagged1 KD leads to a decrease in med12 transcription in self renewing hASCs
Since the knockdown of med12 appeared to result in an increase in transcription
of jagged1, hASCs were transfected with jagged1-specific siRNA to determine if it had
any effect on MED12 transcript or protein. Jagged1 levels were decreased in cell culture
via siRNA transfections, and the knockdowns were validated using qRT-PCR. Jagged1
transcript was significantly reduced in comparison to negative controls, confirming the
knockdown (Figure 3-17). Med12 transcript appeared to decrease significantly,
suggesting a possible relationship between Notch signaling and med12 expression (Figure
3-18).
Jagged1

P value= 0.00092
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Figure 3-17: Jagged1 knockdown leads to a decrease in jagged1 transcript.
Transcript expression levels of hASCs transfected with jagged1 siRNA analyzed
via qRT-PCR. Data was normalized to GAPDH. N=3.

MED12

P value= 0.008868

Figure 3-18: Jagged1 knockdown leads to decrease in med12 transcript.
Transcript expression levels of hASCs transfected with jagged1 siRNA analyzed
via qRT-PCR. Med12 expression levels decreased significantly. Data was
normalized to gapdh. N=3.

Jagged1 KD leads to an increase in jagged2 transcription in self-renewing hASCs
Once both jagged1 and jagged2 expression levels were assessed following the
knockdown of med12, we decided to investigate the relationship between the Jagged1
and Jagged2 ligands. Jagged1 was once again knocked down using siRNA and levels of
jagged 2 were evaluated. Jagged1 levels were decreased in cell culture via siRNA
transfections, and the knockdowns were validated using qRT-PCR (3-17). Jagged1
transcript was significantly reduced in comparison to negative controls, confirming the
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knockdown. Conversely, jagged2 transcript levels increased (Figure 3-19). These data
suggests that Jagged1 may have an inverse relationship with Jagged2.

Jagged2

P = 0.450378

Figure 3-19: Jagged1 knockdown leads to an increase in jagged2 transcript.
Transcript expression levels of jagged2 hASCs transfected with jagged1 siRNA
analyzed via qRT-PCR. Jagged2 expression levels increased, but not significant.
Data was normalized to gapdh. N=3.

Influence of Jagged2 KD on med12 transcription in self renewing hASCs could not be
determined
Since the data suggested the knockdown of med12 increases transcription of
jagged2, the trend was further investigated by transfecting hASCs with jagged2 siRNA to
determine if it had any effect on MED12 transcript or protein. Jagged2 levels were
decreased in cell culture via siRNA transfections, but the knockdowns were unable to be
validated using qRT-PCR, as jagged2 transcript increased following siRNA transfection
(Figure 3-20). Although med12 transcript decreased in comparison to negative controls,
it’s relationship with Jagged2 remains undetermined since the jagged2 knockdown was
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not able to be validated (Figure 3-21). Because of this, Jagged2 assays need to be
optimized and repeated. There are plans to continue working with Jagged2 to further
analyze its role in Notch and Mediator interactions, but it may not be expressed at high
levels.
Jagged2
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P = 0.875875

Figure 3-20: Jagged2 knockdown was unable to be confirmed. Transcript
expression levels of jagged2 hASCs transfected with jagged2 siRNA analyzed
via qRT-PCR. Data was normalized to gapdh. N=3.
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Figure 3-21: Jagged2 knockdown was unsuccessful, therefore its effect on
med12 transcript is undetermined. Transcript expression levels of med12
hASCs transfected with jagged2 siRNA analyzed via qRT-PCR. Data was
normalized to gapdh. N=3.

The influence of Jagged2 KD on jagged1 transcription in self renewing hASCs could
not be determined
Finally, the relationship between Jagged1 and Jagged2 needed to be investigated.
This was done by first transfecting hASCs with jagged2-specific siRNA to determine if it
had any effect on Jagged1 transcript or protein. Jagged2 levels were decreased in cell
culture via siRNA transfections, but the knockdowns were unable to be validated using
qRT-PCR and western blot. The jagged2 knockdown was unable to be confirmed, as
jagged2 transcription increased following transfection of the siRNA (Figure 3-20).
Jagged1 transcript did not change in comparison to negative controls, which was to be
expected since the knockdown was not able to be validated (Figure 3-22). These data
prevented us from further investigating the relationship of the Jagged ligands with each
other. Because of this, Jagged2 assays needs to be optimized and repeated.
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0.4
0.2
0
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Fold change
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Figure 3-22: Jagged2 knockdown was unable to be confirmed, therefore its
effect on jagged1 transcript is undetermined. Transcript expression levels of
jagged1 hASCs transfected with jagged2 siRNA analyzed via qRT-PCR. Data was
normalized to gapdh. N=3.
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CHAPTER 4

CONCLUSION AND FUTURE WORK

4.1 Conclusion
Stem cells have tremendous potential to aid in regenerative medicine and the
treatment of injury and degenerative disease. In order to realize this potential, we must
first understand the factors that regulate cell state. Here we continued work to understand
the relationship between Notch signaling pathway and the Mediator complex in attempt
to uncover the mechanisms responsible for regulating stem cell fate.
In order to study the influence of specific factors on human adipose-derived stem
cells, we used target-specific siRNA-mediated knockdowns. These knockdowns target
mRNA to temporarily diminish expression of the targeted gene transcripts and ultimately
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decrease protein expression, allowing researchers to determine the function or role of a
specific gene and its protein product. I used knockdowns to isolate and study MED12,
Notch1, Notch3, Jagged1, and Jagged2 and their influence in human adipose stem cells.
The relationship between notch1 and notch3 was explored via qRT-PCR. We
observed that the knockdown of notch1 in hASCs results in increased notch3
transcription. Although the data was not significant, it indicates a potential inverse
relationship between the Notch receptors. These experiments need to be repeated for
further validation using Western blot and analysis of protein expression. In addition, there
are plans to continue working with Notch3 to further analyze its role in Notch and
Mediator interactions as well.
The relationship between notch1 and the jagged ligands was also explored via
qRT-PCR. The knockdown of notch1 decreased jagged1 transcription but increased
jagged2 transcription, indicating the Jagged ligands have an inverse relationship with
each other, and encouraging us to further investigate their relationship.
The relationship between notch1 and med12 was explored via qRT-PCR. The
knockdown of notch1 led to a decrease in med12 transcript, but the data was not
significant. Previous data in lab showed similar results, but more experiments need to be
run to confirm these data, as well as analysis of protein expression through Western blot.
We observed that the knockdown of MED12 in hASCs results in diminished
Notch3 expression. We also observed that the knockdown of notch3 reduced the amount
of med12 transcript in hASCs. These data indicate a potentially significant relationship
between MED12 and Notch3 that may have a role in regulating cell state.
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The relationship between med12, jagged1, and jagged2 was also explored via
qRT-PCR. We found that med12 knockdown does not affect jagged1 or jagged2 ligand
transcription in self-renewing hASCs. Although there was a slight increase in jagged1
and jagged2 transcript observed following the knockdown of med12, neither were
significantly affected.
Jagged1 knockdowns were performed to evaluate the influence of this ligand on
med12 and jagged2 transcription. After the knockdown of jagged1 was confirmed by
qRT-PCR, med12 transcript appeared to decrease significantly. This suggests a possible
relationship between Notch signaling and med12 expression. We also found that the
knockdown of jagged1 leads to an increase in jagged2 transcription in self-renewing
hASCs, suggesting an inverse relationship between the two ligands. It is possible that
MED12 expression is affected by JAG1 but not by JAG2, however, more experiments
need to be run to confirm this (Figure 4-1)
There are plans to continue working with Jagged2 to further analyze its role in
Notch and Mediator interactions, but I believe the jagged2 knockdown may not have
worked because Jagged2 is not highly expressed in hASCs. If Jagged2 is already
minimally present to start, isolating it becomes a challenge. It may be beneficial in the
future to see if it is present in a higher volume in other cell types, such as BMSCs.

A
.

51

B
.

Figure 4-1: Summary figure that shows the relationships of MED12, Notch1,
Notch3, Jagged1, and Jagged2. A. Transcript summary figure. B. Protein
expression summary figure. MED12 knockdown leads to decreased expression and
activation of Notch3; MED12 may be required to regulate the transcript and
expression of Notch3. Notch3 knockdown leads to decrease MED12 transcript and
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protein; Notch3 may be required to maintain appropriate levels of MED12
expression. Jagged1 knockdown leads to a decrease in MED12 transcript, but has
no discernable effects on protein expression. More research is needed to investigate
the relationship between Jagged1 and Notch3.

Unfortunately, not all of my work was able to be confirmed by Western Blot and
analysis of protein expression. Specifically, there were challenges in assays related to
both Jagged 1 and Jagged2, as well as Notch3. There were several adjustments made in
order to optimize the Western blot protocol, including altering the PAGE concentration
from a 4-15% gel to a 7.5% gel. The 4-15% gels are standard in our lab, and detect 15250kD. Jagged1 bands show at 180kD, and Jagged2 bands show at 150kD, so in theory
they should be detectable by our standard gels. Notch3 is expressed at 300kD, so by
switching gels we were hoping to be able to capture all of these gene’s expressions,
especially since they are on the higher end. We also hoped switching to a gel with a lower
PAGE concentration would allow our gels to run for longer than the standard 90 minutes,
losing the lower molecular weight proteins while allowing resolution and visualization of
higher molecular weight proteins. In addition, we also adjusted sample boiling time both
increasing time from the standard 10-minute period to 15 and 20 minutes, and decreasing
time to 8, 5, and 3 minutes. In a final attempt to see Jagged1 and Jagged2, the
concentration of antibody used was increased. Despite these protocol modifications, we
continued to be unable to detect Jagged2 protein and suspect that expression might just be
too low in hASCs to detect or necessarily warrant further investigation.
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4.2 Future Directions
Work in the Newman lab continues to be performed to validate these results and
look further into the role of these proteins in self-renewal. Specifically, since preliminary
data shows an influence of MED12 on Jagged1 and Jagged2 transcription, we need to
validate changes at protein level. We are also planning to examine MED12 knockdown
influence on other Notch ligands such as DLL1, DLL3, and DLL4. If we determine that
one of the five Notch ligands is significantly affected by the MED12 knockdown, either
increased or decreased, the next objective will be to knockdown that specific ligand and
work to determine the influence of that ligand on MED12, Notch1, or Notch3 expression
and hASC self-renewal. We can also observe the non-canonical Notch signaling pathway
by knocking down MED12 and determining the potential role of non-canonical ligands,
specifically DLK1 and DLK2, in controlling hASC self-renewal. Finally, in order to
determine the global changes in gene expression following the knockdown of any one of
these critical transcriptional regulatory, we could perform microarray analysis or RNASeq. Understanding of how we can control the fate of stem cells, will allow manipulation
so that stem cells may be used to their full potential in regenerative medicine.

4.3 Significance
Researchers have been looking for an alternative to bone marrow-derived
mesenchymal stem cells for therapeutic usage due to the highly invasive donation
procedure, as well as the decline in MSC number and differentiation potential with
increasing age. Because of this, human adipose derived stem cells are being used in
clinical trials and research, and are proven to work as alternative sources of mesenchymal
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stem cells. Human ASCs have only recently become more common in clinics and
research labs, meaning that their self-renewal and differentiation mechanisms are not yet
well understood. Our work seeks to uncover mechanisms of cell state regulation that will
allow for greater clinical application of these cells in the future.
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